2.3 Endpoints and subanalyses
Efficacy outcomes included
NASH resolution, glycated hemoglobin (HbA1c), serum triglycerides,
high-density lipoprotein (HDL), low-density lipoprotein (LDL), PRO-C3,
and body weight. Adverse events were the safety outcome of interest.
Prespecified subanalysis included FGF21 analog dosing data: (1) low
dose: 3 mg to 18 mg; (2) medium dose: 20 mg to 36 mg; and (3) high dose:
higher than 40 mg.